VIRX · Viracta Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $7.18M | $6.55M | $9.96M | - | $8.16M | $8.20M | $7.61M | - | $7.14M | $6.32M |
| SG&A | $3.00M | $3.04M | $3.92M | - | $4.32M | $4.25M | $4.60M | - | $10.94M | $4.18M |
| Total Operating Expenses | $10.19M | $9.59M | $13.88M | - | $12.47M | $12.45M | $12.21M | - | $18.08M | $10.51M |
| D&A | - | - | $110.0K | - | - | - | $122.0K | - | - | - |
| Operating Income | ($10.19M) | ($9.59M) | ($13.88M) | - | ($12.47M) | ($12.45M) | ($12.21M) | - | ($18.08M) | ($10.51M) |
| Interest Expense | $679.0K | $697.0K | $858.0K | - | $953.0K | $921.0K | $880.0K | - | $139.0K | $127.0K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($10.55M) | ($9.83M) | ($9.14M) | - | ($12.60M) | ($12.48M) | ($12.21M) | - | ($17.74M) | ($10.58M) |
| EPS - Basic | ($0.27) | ($0.25) | ($0.23) | - | ($0.33) | ($0.32) | ($0.32) | - | ($0.40) | ($0.25) |
| EPS - Diluted | ($0.27) | ($0.25) | ($0.23) | - | ($0.33) | ($0.32) | ($0.32) | - | - | - |
Balance Sheet
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.13M | $13.98M | $12.06M | $12.32M | $12.86M | $14.29M | $18.10M | $36.77M | $23.47M | $81.58M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.82M | $1.29M | $2.41M | $2.44M | $2.36M | $3.23M | $2.08M | $2.54M | $1.62M | $1.83M |
| Current Assets | $21.80M | $31.07M | $40.95M | $54.96M | $64.44M | $74.56M | $83.42M | $93.75M | $79.68M | $86.36M |
| Total Assets | $21.96M | $31.32M | $41.33M | $56.69M | $66.44M | $76.86M | $85.78M | $95.99M | $82.20M | $89.16M |
| Current Liabilities | $28.57M | $28.65M | $30.25M | $38.37M | $36.43M | $15.21M | $11.65M | $10.01M | $9.39M | $7.22M |
| Long-term Debt | $16.91M | $18.75M | $18.68M | $0 | $0 | $20.79M | $22.83M | $24.88M | $4.87M | $4.86M |
| Total Liabilities | $28.57M | $28.65M | $30.25M | $38.37M | $36.43M | $34.89M | - | - | - | - |
| Stockholders' Equity | ($6.62M) | $2.67M | $11.08M | $18.32M | $30.01M | $40.78M | $51.11M | $61.10M | $67.81M | $77.00M |
| Retained Earnings | ($295.46M) | ($284.90M) | ($275.07M) | ($265.93M) | ($252.17M) | ($239.57M) | ($227.08M) | ($214.87M) | ($204.55M) | ($186.81M) |
Cash Flow
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($7.85M) | - | - | - | ($11.34M) | - | - | - |
| Investing Cash Flow | - | - | $14.19M | - | - | - | ($7.35M) | - | - | - |
| Financing Cash Flow | - | - | ($6.60M) | - | - | - | $16.0K | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -48.1% | -31.4% | -22.1% | - | -19.0% | -16.2% | -14.2% | - | -21.6% | -11.9% |
| Return on equity | 159.5% | -368.0% | -82.5% | - | -42.0% | -30.6% | -23.9% | - | -26.2% | -13.7% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.76 | 1.08 | 1.35 | 1.43 | 1.77 | 4.90 | 7.16 | 9.36 | 8.49 | 11.96 |
| Quick ratio | 0.76 | 1.08 | 1.35 | 1.43 | 1.77 | 4.90 | 7.16 | 9.36 | 8.49 | 11.96 |
| Cash ratio | 0.46 | 0.49 | 0.40 | 0.32 | 0.35 | 0.94 | 1.55 | 3.67 | 2.50 | 11.30 |
| Leverage | ||||||||||
| Debt / Equity | -2.56 | 7.02 | 1.69 | 0.00 | 0.00 | 0.51 | 0.45 | 0.41 | 0.07 | 0.06 |
| Debt / Assets | 0.77 | 0.60 | 0.45 | 0.00 | 0.00 | 0.27 | 0.27 | 0.26 | 0.06 | 0.05 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -15.0x | -13.8x | -16.2x | - | -13.1x | -13.5x | -13.9x | - | -130.1x | -82.7x |
| Equity multiplier | -3.32 | 11.73 | 3.73 | 3.09 | 2.21 | 1.88 | 1.68 | 1.57 | 1.21 | 1.16 |
| Liabilities / Assets | 1.30 | 0.91 | 0.73 | 0.68 | 0.55 | 0.45 | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 18.4% | 23.0% | -13.7% | - | 31.0% | -18.5% | -17.0% | - | -22.2% | -12.8% |
| Net income growth (YoY) | 16.2% | 21.3% | 25.1% | - | 29.0% | -18.0% | -15.8% | - | -19.0% | -15.4% |
| EPS growth (YoY) | 18.2% | 21.9% | 28.1% | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | -93.5% | -78.3% | -70.0% | -55.7% | -47.0% | -40.3% | -35.3% | -34.8% | -34.2% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Viracta Therapeutics against the 5 most active filers in the same SIC group.